Abstracts Archive - Page 116 of 2425 - ACR Meeting Abstracts

Abstract Number: 1006 • ACR Convergence 2024
Associations Between Rheumatic Diseases and Mental Health Disorders
Thoai Vu, Sivam Bhatt and Janet Lewis, University of Virginia, Charlottesville, VA
Background/Purpose: Rheumatic diseases are frequently linked to a reduced quality of life (QoL), particularly as disease severity escalates. Patients with rheumatic conditions often exhibit high…
Abstract Number: 1448 • ACR Convergence 2024
The Proportion of Inflammatory Back Pain Patients with an Abnormal Sacral MRI in a Community-Based Primary Care Setting
Emmanuel Katsaros¹, Robb Russel², Melissa Nagare², Cesar Ochoa¹, Fanglong Dong¹ and Michael Weisman³, ¹Western University of Health Sciences, Pomona, CA, ²Southern California University of Health Sciences, Whittier, CA, ³Stanford University, Los Angeles, CA
Background/Purpose: Axial spondyloarthritis (axSpA) is a group of disorders typically occurring before the age of 45 whose common features include disabling inflammatory arthritis of the…
Abstract Number: 1262 • ACR Convergence 2024
The Relationship Between Child Opportunity Index and Burden of Pediatric Systemic Lupus Erythematosus
Ayah Eltoum¹, Livie Timmerman², Melissa Mannion¹ and Emily Smitherman¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Gardendale, AL
Background/Purpose: Outcomes for systemic lupus erythematosus are known to be associated with sociodemographic indicators. The Child Opportunity Index (COI) is a well-validated measure of neighborhood…
Abstract Number: 1456 • ACR Convergence 2024
Real-World Treat-to-Target Strategy in Psoriatic Arthritis: Baseline Characteristics from the MONITOR-PsA Cohort
Lija James¹, Elnaz Saeedi², Jean-Guillaume Letarouilly¹, Nicola Gullick³, Anne Francis², Deepak Jadon⁴, William Tillett⁵, Yvonne Sinomati², Laura Tucker¹, Nadia Mian², Ines Rombach², Ioana Marian², Maria Sofia Massa² and Laura Coates⁶, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Oxford Clinical Trials Research Unit, University of Oxford, Oxford, United Kingdom, ³Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, Coventry, United Kingdom, ⁴Cambridge University, Cambridge, United Kingdom, ⁵Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ⁶University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is a chronic musculoskeletal disease, which can lead to progressive joint pain, joint destruction, and loss of function. Evidence suggests that…
Abstract Number: 1457 • ACR Convergence 2024
Treat-to-Target Approaches in Early Psoriatic Arthritis: Early Secukinumab versus Standard Care – 12- and 24-Week Results from a Multicenter, Open-Label, Randomized Controlled Trial
Gonul Hazal Koc¹, Marc R. Kok², Fazira R. Kasiem³, Jolanda Luime³, Ilja Tchetverikov⁴, Kim Wilhelm - de Jong³, Lindy A. Korswagen⁵, Jessica Bijsterbosch⁶, Yvonne P. M. Goekoop-Ruiterman⁷, Paul Baudoin⁸, Petra Kok⁹, Reinhard Bos¹⁰, radboud J.e.m. Dolhain¹¹ and Marijn Vis³, ¹Erasmus MC, Rotterdam, Zuid-Holland, Netherlands, ²Maasstad Hospital, Rotterdam, Netherlands, ³Erasmus MC, Rotterdam, Netherlands, ⁴Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁵Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands, ⁶Amphia Hospital, North Brabant, Netherlands, ⁷Haga Hospital, Den Haag, Netherlands, ⁸Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁹Reinier de Graaf Gasthuis, Delft, Netherlands, ¹⁰Medical Center Leeuwarden, Leeuwarden, Netherlands, ¹¹Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose: The Strategy Treatments aiming at Minimal Disease Activity in PsA (STAMP) is a one-year randomized controlled trial designed to investigate the efficacy of two…
Abstract Number: 1453 • ACR Convergence 2024
Efficacy and Safety of the Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection (XKH004) in Patients with Active Ankylosing Spondylitis: Findings from a 24-Week, Phase 2 Multicenter, Randomized, Placebo-Controlled Study
Ling Zhou¹, Juan Zhao¹, Lingyun Sun², Xuan Zhang³, Xiaomei Li⁴, Jiankang Hu⁵, Lijun Wu⁶, Zhenyu Jiang⁷, Min Yang⁸, Xiaoxia Wang⁹, Yongjun Mei¹⁰, Qingchun Huang¹¹, Yongtao Chen¹², Yang Li¹³, Lingli Dong¹⁴, Hui Luo¹⁵, Li Guo¹⁶, Jianguo You¹⁶, Yunpeng Zhang¹⁶, Ke Ren¹⁶ and Huji Xu¹, ¹Shanghai Changzheng Hospital, Shanghai, China (People's Republic), ²Nanjing Drum Tower Hospital, Nanjing, China (People's Republic), ³Beijing Hospital, Beijing, China, ⁴The First Affiliated Hospital of University of Science and Technology of China, Anhui, China (People's Republic), ⁵Department of Rheumatology, Pingxiang People's Hospital, Pingxiang, China, Pingxiang, China (People's Republic), ⁶People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China (People's Republic), ⁷The First Hospital of Jilin University, Changchun, China (People's Republic), ⁸Nanfang Hospital, Guangzhou, China (People's Republic), ⁹Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), ¹⁰The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ¹¹The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China (People's Republic), ¹²West China Hospital, Sichuan University, Chengdu, China (People's Republic), ¹³Guangdong Provincial People's Hospital, Guangzhou, China (People's Republic), ¹⁴Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (People's Republic), ¹⁵Xiangya Hospital, Central South University, Changsha, China (People's Republic), ¹⁶Kanova Biopharma, Zhejiang, China (People's Republic)
Background/Purpose: XKH004, the first recombinant anti-human IL-17A/F humanized monoclonal antibody in China (also known as XKH004), shares the same therapeutic target as Bimekizumab from UCB…
Abstract Number: 1463 • ACR Convergence 2024
Investigation of the Cardiometabolic-related Mechanism of Action of Apremilast Through Plasma Proteomics Profiling of Patients with Psoriasis or Psoriatic Arthritis from Three Phase 3 Studies
A. Francesca Setiadi¹, Maggie Burhans², Xuguang Hu², Stephen Colgan³, Kim Notari², Marcia C. Teixeira dos Santos², Apostolos Kontzias², Sue Cheng² and Nehal Mehta⁴, ¹Amgen Inc., South San Francisco, CA, ²Amgen Inc., Thousand Oaks, CA, ³Amgen, Halton Hills, ON, Canada, ⁴The George Washington University School of Medicine, Washington, DC
Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are associated with higher rates of obesity and cardiometabolic complications. Apremilast (APR) is an inhibitor of phosphodiesterase 4,…
Abstract Number: 1394 • ACR Convergence 2024
Nationwide Retrospective Cohort Study on Clinical Outcomes in Rheumatoid Arthritis Patients Treated with JAK Inhibitors
Yurilu Gonzalez Moret¹, Diego Lema² and Fabian Rodriguez Quinonez³, ¹Jefferson Einstein Hospital, Philadelphia, PA, ²Universidad Central de Venezuela, University of Wisconsin, Philadelphia, PA, ³Einstein Medical Center Philadelphia, Philadelphia, PA
Background/Purpose: Janus kinase inhibitors (JAKi) are a class of disease activity-modifying drugs (DMARDs) that have quickly established a role in managing rheumatoid arthritis. Inhibition of…
Abstract Number: 1272 • ACR Convergence 2024
Angiopoietin-2 and Soluble Tumor Necrosis Factor Receptor Type II Are Elevated in Treatment Naïve JDM Plasma and Associate with Increased Muscle Disease Activity and Decreased Nailfold Capillary Density
Sophia Matossian¹, Julie Sturza², Megan Mattichak¹, William Brodie¹, Christine Goudsmit¹, Nicholas McClellan¹, J. Michelle Kahlenberg¹, Pei-Suen Tsou¹ and Jessica Turnier³, ¹University of Michigan, Ann Arbor, MI, ²Michigan Medicine Biostatistics and Data Management, Ann Arbor, MI, ³University of Michigan, Saline, MI
Background/Purpose: Juvenile Dermatomyositis (JDM) is an autoimmune disease characterized by vasculopathy in skin and muscle, where endothelial cell (EC) dysfunction is thought to contribute to…
Abstract Number: 1462 • ACR Convergence 2024
Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab versus Subcutaneous IL-17A Inhibitors
Philip Mease¹, Ruizhi Zhao², Shannon Ferrante³, Natalie J. Shiff⁴, Pavithra Srinivas⁵, Soumya Chakravarty⁶ and Jessica A Walsh⁷, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Janssen Scientific Affairs, LLC, Titusville, NJ, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Janssen Scientific Affairs, LLC / University of Saskatchewan, Adjunct, Community Health and Epidemiology, Horsham, PA, ⁵Janssen Scientific Affairs LLC, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, Horsham/ Drexel University College of Medicine, Philadelphia, Horsham, PA, ⁷Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT
Background/Purpose: Guselkumab, a fully human IL-23p19-subunit inhibitor, has demonstrated significant and durable efficacy and high rates of patient retention in randomized controlled trials of adults…
Abstract Number: 1475 • ACR Convergence 2024
Baseline Characteristics and Efficacy in Patients with Radiographic AxSpA (r-axSpA) Stratified by CRP Level: An Analysis from the Ixekizumab Phase III Trial
Raj Sengupta¹, Pedro M Machado², Philippe Goupille³, Victoria Navarro Compán⁴, Huji Xu⁵, mohamed sheesh⁶, Khai Jing Ng⁷, Marcus Ngantcha⁸, Hagen Russ⁹, Gabriel Doridot⁶ and Xenofon Baraliakos¹⁰, ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, ³UPR CNRS 4301 CBM, NMNS, University of Tours; Department of Rheumatology, University hospital, Tours, Tours, France, ⁴La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ⁵Changzheng Hospital, Naval Medical University, Shanghai, China, Shanghai, China (People's Republic), ⁶Eli Lilly, Indianopolis, IN, ⁷Eli Lilly and Company, Madrid, Spain, ⁸Eli Lilly and Company, Indianapolis, IN, ⁹Eli Lilly, Indianopolis, ¹⁰Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Elevated baseline (BL) C-reactive protein (CRP) level can serve as a predictor for treatment response to TNF inhibitors in patients (pts) with r-axSpA. The…
Abstract Number: 1030 • ACR Convergence 2024
Diversity in Axial Spondyloarthritis Drug Trials: Examining Enrollment by Sex, Race, Ethnicity and Geographic Region
Mathieu Choufani¹, Wissam Ghusn² and Joerg Ermann³, ¹Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ²Department of Internal Medicine, Boston Medical Center, Boston, MA, ³Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: While axial spondyloarthritis (AxSpA) was historically perceived as a "white man's disease", it is now appreciated as a condition that can affect individuals of…
Abstract Number: 1404 • ACR Convergence 2024
Modeling Diversity in Systemic Lupus Erythematosus (SLE) Clinical Trials Using Real-world Data (RWD) Sources
Andrew Bevan¹ and Nora Carroll², ¹Integrated Project Solutions, PPD, part of Thermo Fisher Scientific, Cambridge, United Kingdom, ²Cardiovascular and General Medicine, Thermo Fisher Scientific, Athlone, Ireland
Background/Purpose: The FDA places emphasis on studying clinically relevant trial populations but does not address how these might be defined. SLE disproportionately affects women and…
Abstract Number: 1405 • ACR Convergence 2024
Perceived Healthcare Discrimination Among Individuals with Musculoskeletal Conditions: A Retrospective Cross-Sectional Analysis
Titilayo Adeniran¹, Bertilia Trieu², Sandra Goldsmith¹ and Laura Robbins¹, ¹Hospital for Special Surgery (HSS), New York, NY, ²Hospital for Special Surgery, New York, NY
Background/Purpose: Musculoskeletal conditions, including osteoarthritis (OA), osteoporosis (OP), rheumatoid arthritis (RA), and chronic pain, significantly burden individuals' health and well-being. These conditions often lead to…
Abstract Number: 1294 • ACR Convergence 2024
Using Case-Based Continuing Education to Identify and Address Knowledge and Behavior Gaps in ANCA-associated Vasculitis
Bharati Hegde, Jillian Scavone, Katie Robinson and Robert Esgro, Vindico Medical Education, West Deptford, NJ
Background/Purpose: Given the rarity and non-specific symptoms associated with ANCA-associated vasculitis (AAV), rheumatology clinicians are challenged to use best practices for patient recognition and management,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].